Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
Revenue (TTM)
$2 Mln
Net Profit (TTM)
$0 Mln
ROE
-8.4 %
ROCE
-- %
P/E Ratio
1.1
P/B Ratio
4.9
Industry P/E
--
EV/EBITDA
-0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.6
Face value
--
Shares outstanding
2,033,072
CFO
$-89.64 Mln
EBITDA
$-168.55 Mln
Net Profit
$-10,133,143.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Qualigen Therapeutics (QLGN)
| -7.5 | -15.3 | -36.0 | -42.8 | -66.7 | -73.2 | -67.6 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Qualigen Therapeutics (QLGN)
| -40.1 | -84.5 | -57.3 | -88.0 | -64.5 | -28.7 | -71.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective... transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California. Read more
President, COO, CEO & Chairman
Mr. Michael S. Poirier
President, COO, CEO & Chairman
Mr. Michael S. Poirier
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Qualigen Therapeutics Inc (QLGN) is $2.33 (NASDAQ) as of 20-Jan-2026 09:30 EDT. Qualigen Therapeutics Inc (QLGN) has given a return of -66.72% in the last 3 years.
The P/E ratio of Qualigen Therapeutics Inc (QLGN) is 1.13 times as on 20-Jan-2026.
The P/B ratio of Qualigen Therapeutics Inc (QLGN) is 4.91 times as on 20-Jan-2026, a 25 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.50
|
1.16
|
|
2023
|
-0.21
|
-1.37
|
|
2022
|
-0.26
|
0.75
|
|
2021
|
-0.19
|
0.20
|
|
2020
|
-0.35
|
0.39
|
The 52-week high and low of Qualigen Therapeutics Inc (QLGN) are Rs 8.81 and Rs 1.61 as of 04-Apr-2026.
Qualigen Therapeutics Inc (QLGN) has a market capitalisation of $ 7 Mln as on 20-Jan-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Qualigen Therapeutics Inc (QLGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.